If there’s one company in Europe that knows how to communicate, it’s the prolific cardiology and vascular device and remote monitoring outfit, Biotronik. Not only does the German-based entity seem to churn out new and of-the-minute offerings with relentless frequency, it certainly knows how to plug them as well. As if to prove the point the company has now introduced its Pulsar stent technology in a 0.035″/6F platform, building on what it claims is the success of its Pulsar 18, 0.018″/4F version.
Biotronik says the addition of the Pulsar-35 self-expanding stent system will make its proven stent technology available to even more clinicians. It’s claims include a triaxial delivery system designed to provide precise implantation accuracy, and the system benefits from the same outstanding stent design as the Pulsar-18—including features such as high multiaxis flexibility and optimised radial force specifically designed for the challenges of Superficial Femoral Artery (SFA) stenting. Available in lengths from 30 mm to 200 mm and diameters of 5 mm to 7 mm, this stent will provide an additional treatment option with promising clinical data.
And…Passeo-14 infrapop PTA balloon catheter
Getting greedy now, the company has doubled up its new product release with news of the Passeo-14 balloon catheter, a dedicated 0.014″ infrapopliteal percutaneous transluminal angioplasty (PTA) catheter. Biotronik says it has designed the new catheter in order to address weaknesses common to infrapopliteal PTA catheters, by working in collaboration with infrapopliteal experts.
Key features include a stiffened proximal catheter shaft and hydrophilic coating for excellent push transmission and crossability—plus a balloon-diameter-specific distal shaft length that provides optimised flexibility in tortuous pedal anatomy. Available in balloon lengths of up to 220 mm, Biotronik claims this device may shorten procedure times and could reduce the need for multiple inflations.
“The Pulsar-35 self-expanding Stent and Passeo-14 PTA balloon catheter greatly improve Biotronik’s ability to meet physician needs and deliver best-in-class technology with flexibility for different treatment options,” said Alain Aimonetti, Vice President of Sales and Marketing, Biotronik Vascular Intervention. “Our robust product and clinical pipeline will continue to make Biotronik a leader in peripheral vascular innovations, and these latest clinical and product developments underscore the strength and performance of Biotronik’s unique lower limb portfolio and our continuing commitment to delivering technological excellence backed by scientific evidence.”
Source: Biotronik AG